National Institute of Allergy and Infectious Diseases (NIAID)
Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body. They want to see if they can locate the malaria parasites in the body using imaging scans. Objective: To learn whether imaging scans can locate parasites in people with malaria. Eligibility: Healthy people aged 18 to 54 years. They must be enrolled in protocol IRB001970 or IRB002627 for controlled malaria infection. Design: Participants will be screened. They will have blood drawn and a physical exam, including an abdominal exam to check the size of their spleen. Participants for this study will have 2 or 3 positron emission tomography/computed tomography (PET/CT) scans: The first will be about 3 days before they are deliberately infected with malaria for a different study. The second will be about 13 days later, while they have the disease. The third scan is optional; it will be done about 3 and 1/2 weeks after the second scan. For each scan, participants will receive a radioactive tracer called fluorodeoxyglucose (FDG). FDG will be injected through a tube inserted into a vein. They will lie on a table that slides through a doughnut-shaped machine. PET/CT uses x-rays to create images of the inside of the body. All participants will have a follow-up visit about 3 and 1/2 weeks after the second scan. The blood draw and physical exam will be repeated. This visit may be combined with the third scan for those who choose it.
Study Description: Participants who are enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center (CC) may be co-enrolled in this single-site study to undergo a 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scan of their chest, abdomen, and pelvis at baseline before controlled human malaria infection (CHMI) inoculation and again at the expected time of peak parasitemia. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection. Other assessments will include inflammatory labs, signs of bone ma…
* INCLUSION CRITERIA In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Aged \>=18 and \<=54 years. 2. Able to provide informed consent. 3. Co-enrolled in NIH protocol IRB001970, "Phase 1 study of induced blood-stage malaria in healthy malaria-naive adults to assess the safety and infectivity of Plasmodium vivax challenge agent and evaluate transmission in mosquito feeding assays" or IRB002627, "Phase 1/2 study of transmission-blocking vaccine Pvs230D1-EPA/Matrix-M in healthy malaria-naive adults using a Plasmodium vivax controlled…
Participants are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center. These participants will undergo up to 3 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scans of their chest, abdomen, and pelvis. PET/CT scans will occur at baseline (before controlled human malaria infection (CHMI) inoculation), and at the expected time of peak parasitemia. Participants may have an optional 3rd PET/CT scan at day 34 after the CHMI inoculation. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection.